image credit: Freepik

Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks

January 6, 2022


Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to the next level. The biotech unveiled the hiring of six new executives as it pulled back the curtain on a more than half-a-billion-dollar fundraising round Thursday.

Eikon’s meaty $517.8 million series B comes on the heels of a $148 million series A round last May, for a total of more than $665 million raised so far over the company’s two-year life span.

Read More on FierceBiotech